CD274 and neoplasm: High levels of tumor heterogeneity in PD-L1 expression in gastric cancer, along with variability across different assays, are some of the key limitations of utilizing tissue PD-L1 expression as the sole biomarker to identify patients that may benefit from ICI in gastric cancer.